Luseogliflozin, a sodium glucose co-transportet-2 inhibitor, alleviates hepatic impairment in Japanese patients with type 2 diabetes mellitus - Kusunoki, M; Sato, D; Natsume, Y (Drug Res, 2016)
et al.